CN112089734A - Application of mussel extract in preparation of medicament for treating flora disorder - Google Patents
Application of mussel extract in preparation of medicament for treating flora disorder Download PDFInfo
- Publication number
- CN112089734A CN112089734A CN202011038359.XA CN202011038359A CN112089734A CN 112089734 A CN112089734 A CN 112089734A CN 202011038359 A CN202011038359 A CN 202011038359A CN 112089734 A CN112089734 A CN 112089734A
- Authority
- CN
- China
- Prior art keywords
- flora
- mussel
- inflammatory
- mussel extract
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000237536 Mytilus edulis Species 0.000 title claims abstract description 77
- 235000020638 mussel Nutrition 0.000 title claims abstract description 74
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 239000002158 endotoxin Substances 0.000 claims abstract description 21
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 14
- 230000000770 proinflammatory effect Effects 0.000 claims abstract description 11
- 235000005911 diet Nutrition 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 241000043362 Megamonas Species 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical group Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims description 2
- 230000000378 dietary effect Effects 0.000 claims description 2
- 230000003828 downregulation Effects 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 32
- 230000000694 effects Effects 0.000 abstract description 16
- 206010061218 Inflammation Diseases 0.000 abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 230000004054 inflammatory process Effects 0.000 abstract description 11
- 208000035475 disorder Diseases 0.000 abstract description 10
- 238000002474 experimental method Methods 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 abstract description 5
- 230000037213 diet Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 230000008859 change Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 208000037487 Endotoxemia Diseases 0.000 abstract description 3
- 239000013543 active substance Substances 0.000 abstract description 3
- 238000009509 drug development Methods 0.000 abstract description 2
- 244000183278 Nephelium litchi Species 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 14
- 241000894007 species Species 0.000 description 12
- 239000000203 mixture Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- 210000003608 fece Anatomy 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000239218 Limulus Species 0.000 description 3
- 241000566145 Otus Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 238000011577 humanized mouse model Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000425347 Phyla <beetle> Species 0.000 description 2
- 241000192142 Proteobacteria Species 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241001495171 Bilophila Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000005787 Cistanche Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241001453172 Fusobacteria Species 0.000 description 1
- BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241001261005 Verrucomicrobia Species 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002884 effect on inflammation Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of biological medicines, and particularly relates to an application of a mussel extract in preparation of a medicine for treating flora disorders. Animal experiments prove that the mussel extract contains various active substances, can adjust the structural change of intestinal flora induced by diet, recover key inflammatory flora to normal abundance, slow down the inflow of endotoxin of inflammatory factors, reduce the expression of proinflammatory factors of organisms, and increase the expression of inflammation-inhibiting factors, so as to achieve the effects of regulating the intestinal flora and treating flora disorder and low-grade endotoxemia caused by the flora disorder. The mussel has rich sources, low cost, high safety, simple preparation method and good drug development foundation.
Description
Technical Field
The invention belongs to the technical field of biological medicines. More particularly, relates to an application of mussel extract in preparing a medicament for treating flora disturbance.
Background
The intestinal flora is a collection of thousands of different bacteria that colonize the gastrointestinal tract of a host, is composed of complex flora that are in mutual communication and mutual restriction, and is a closely-related micro-ecosystem. The different bacterial colonies are combined according to a certain proportion, and the bacterial colonies are restricted and dependent with each other, so that an ecological balance is formed on the quality and quantity. In the long-term evolution process of the intestinal flora, through individual adaptation and natural selection, different species in the flora, flora and host, and flora, host and environment are always in a dynamic balance state to form a system which is interdependent and mutually restricted, so that the flora structure is relatively stable under normal conditions of a human body, and no disease is caused to the host. However, when the environment inside and outside the body changes, such as abuse of antibiotics, bad life style, change of dietary structure, etc., sensitive flora is inhibited, and flora that is not inhibited is propagated by the machine, thereby causing flora imbalance, normal physiological flora combination is destroyed, and a large amount of released endotoxin (LPS) enters the body to induce inflammatory reaction of the body.
At present, common anti-inflammatory drugs such as hydrocortisone, dexamethasone, aspirin, piroxicam and the like have good curative effects on local and systemic infectious inflammations, but have poor curative effects on chronic low-grade inflammations caused by intestinal flora disorder, and the chemicals have certain toxic and side effects and have certain potential safety hazards after long-term use. Many studies indicate that products such as prebiotics and probiotics can regulate intestinal flora, for example, chinese patent application CN102919850A discloses a composition for nutritional food and medicine, which mainly comprises cistanche, probiotics, milk calcium, animal colostrum, etc., and can improve constipation, intestinal flora disorder, and regulate immunity, but has poor therapeutic effect on low-grade endotoxemia caused by intestinal flora disorder.
Disclosure of Invention
The invention aims to solve the technical problems that the existing chemical drugs have poor treatment effect on inflammation caused by flora disturbance and have certain potential safety hazard; although the probiotic products can regulate intestinal flora to a certain extent, the defect and the deficiency of poor treatment effect on low-grade endotoxemia caused by flora disturbance are overcome, and the application of the mussel extract in preparing the medicament for treating the flora disturbance is provided.
The invention aims to provide application of a mussel extract in preparing a medicament for treating flora disturbance.
The above purpose of the invention is realized by the following technical scheme:
mussels are commonly called Qingkou and Haihong and have relatively low value in marine products, but rich resources of the mussels are not well utilized, and the research and development of the mussels have great significance for improving the added value of the mussels. The inventor finds that the mussel extract contains various active substances in practice, and experiments prove that the mussel extract can reduce the expression of proinflammatory factors of an organism, increase the expression of inflammation-inhibiting factors, reduce the concentration of endotoxin of inflammation-causing factors, and achieve the effects of regulating intestinal flora and treating flora disorder and chronic low-grade inflammation caused by the flora disorder.
Therefore, the invention provides an application of the mussel extract in preparing a medicament for treating flora disturbance.
Further, the medicament can reduce the expression of proinflammatory factors of the body.
Still further, the proinflammatory factor is TNF- α.
Furthermore, the medicine can increase the expression of the body inflammation-inhibiting factor.
Further, the anti-inflammatory factor is IL-10.
Further, the medicine can reduce the concentration of endotoxin of the body inflammatory factor.
Further, the drug can restore normal abundance of key inflammatory flora in the gut flora.
Furthermore, the restoration of the normal abundance of key inflammatory flora in the intestinal flora means that the restoration has the effect of reducing and restoring the diversity increase of the intestinal flora induced by diet, and the abundance ratio of the inflammatory driving flora megamonospora and the cholecystokinis is restored.
Further, the preparation method of the mussel extract comprises the following steps:
drying and crushing mussels, adding water with the mass volume ratio of 1 (3-10) g/ml, extracting at 40-60 ℃ for 3-6 h, filtering, adding soluble starch, and spray drying to obtain the mussel extract with the mass of 10% of the mussel raw material.
Preferably, the temperature of the extraction is 50-60 ℃.
The dose of the mussel extract is 4-10 g per 60kg of body weight per time, twice a day and 3-5 days continuously. Can be made into tablet or granule or added into food as medicine or health product for regulating intestinal flora disorder induced by diet, and has effect in lowering and recovering intestinal flora diversity increase induced by diet. The abundance ratio of the inflammatory driving flora megamonospora and the cholecystophila is restored, so that the permeability of an intestinal barrier is reduced, endotoxin LPS is prevented from entering blood, and the level of proinflammatory factors of an organism is remarkably reduced, so that endotoxin infection is controlled, and the immune balance state of the organism is restored.
The invention has the following beneficial effects:
animal experiments prove that the mussel extract contains various active substances, can adjust the diversity change of intestinal flora induced by diet, reduce the expression of proinflammatory factors of organisms, increase the expression of inflammation-inhibiting factors and reduce the concentration of endotoxin of inflammation-causing factors, and achieves the effects of regulating the intestinal flora and treating flora disturbance and chronic low-grade inflammation caused by the flora disturbance. The mussel has rich sources, low cost, high safety, simple preparation method and good drug development foundation.
Drawings
FIG. 1 is a diagram of OTU comparison Wein of dried mussel extract against the abundance of species in the mouse flora.
FIG. 2 is a graph of abundance of species composition at the phylum taxonomic level of Mytilus edulis extract dried prognosis mouse.
FIG. 3 is a graph of abundance of species composition at the taxonomic level of the Mytilus edulis extract dried prognosis mouse flora.
FIG. 4 is a graph showing the analysis of the β -diversity principle components in mice after the mussel extract has been dried.
FIG. 5 is a bar graph of the effect of mussel extract on the expression level of endotoxin (LPS) in serum.
FIG. 6 is a bar graph of the effect of mussel extract on the expression level of the pro-inflammatory factor TNF-. alpha.in serum.
FIG. 7 is a graph showing the effect of mussel extract on the expression level of IL-10, an anti-inflammatory factor in serum.
Detailed Description
The invention is further described with reference to the drawings and the following detailed description, which are not intended to limit the invention in any way. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated.
Unless otherwise indicated, reagents and materials used in the following examples are commercially available.
The statistical processing method comprises the following steps: data analysis was performed using SPSS 22.0 statistical software. The One-way Anova analysis was used for the case of the variance, the nonamerametric tests were used for the case of the variance, the Turkey HSD with multiple tests was used for the group comparison, the counts were expressed as percentages (%), the test level α was 0.05, and the difference p <0.01 was statistically significant.
Example 1A mussel extract
The preparation method of the mussel extract comprises the following steps:
taking 100g of dried mussel, grinding into powder, adding 500ml of water, extracting at 50 ℃ for 4h, filtering to remove residues, adding soluble starch into the filtrate, and spray drying to obtain the mussel extract with the mass of 10% of the mussel raw material.
Example 2A mussel extract
The preparation method of the mussel extract comprises the following steps:
taking 100g of dried mussel, grinding into powder, adding 1000ml of water, extracting at 60 ℃ for 3h, filtering to remove residues, adding soluble starch into the filtrate, and spray drying to obtain the mussel extract with the mass of 10% of the mussel raw material.
Example 3A mussel extract
The preparation method of the mussel extract comprises the following steps:
taking 100g of dried mussel, grinding into powder, adding 300ml of water, extracting at 40 ℃ for 6h, filtering to remove residues, adding soluble starch into the filtrate, and spray drying to obtain the mussel extract with the mass of 10% of the mussel raw material.
Application example 1 Effect of mussel extract on the disturbance of the flora in mice caused by litchi
1. Experimental Material
1.1 Experimental animals:
female mice 8 weeks old, SPF grade C57 BL/6J, weighing 20 + -5 g (purchased from Beijing Huafukang Biotech GmbH, Inc., license number SCXK (Kyoto) 2014007). Experimental animals are raised in metabolic cages in which irradiation-level maintenance feed and sterile water for irradiation sterilization are given, the raising environment temperature is 20-25 ℃, the relative humidity is 40-70%, the light and dark cycle period is 12 hours, fresh air flows in a single direction, the air cleanliness reaches 1 ten thousand level, automatic adjustment and control can be realized, water bottle replacement and padding replacement are carried out 3 times per week, and the animals are fasted for 12 hours before the experiment starts.
1.2 Experimental reagents:
mussel extract: the mussel extract prepared in example 1 was used.
Microplate quantitative chromogenic matrix method limulus kit; ELISA inflammatory index rapid detection Kit, ELISA Kit Product Manual: IL-10 and TNF-alpha ELISA kits of Xinbo Sheng QuantiCyto mice are selected in the experiment; endotoxin rapid detection kit: selecting a limulus kit (microplate quantitative color development method) for detecting endotoxin of Xiamen limulus reagent biotechnology, Inc., batch number: 19080106.
2. laboratory animal treatment
2.1 establishment of intestinal flora humanized mouse (HFA) model
Intragastric mouse antibiotic mixed liquor (vancomycin 200 mg/kg. d)-1 Neomycin 200 mg/kg. d-1Jiaxiao file 200 mg/kg. d-1) Lasting for 3 days;
collecting 1 fresh feces discharged by 1 st morning from 1 healthy volunteer (male, 19 years old, no digestive tract disease, no metabolic disease, no antibiotics taken within 3 months), weighing the feces under anaerobic and sterile conditions, adding 0.1M PBS buffer solution to dilute the feces according to the mass ratio of 1:9, shaking, mixing uniformly, and taking supernatant to obtain feces suspension; the feces suspension of 20 pseudo-sterile mice of healthy volunteers after gastric administration is 0.3mL and 1 time every other day, and HFA mice are obtained after human intestinal flora colonizes in the intestinal tracts of the mice for 3 weeks.
2.2 establishment of mouse endotoxin infection model caused by litchi:
randomly dividing 25 mice of the obtained HFA model into 5 groups, and dividing each group into 5 mice; 5 of the HFA mice served as a control group (designated as HFA), and were perfused with sterile water for 7 days, and the other 4 groups were administered with 1600 mg/kg. d-1The litchi powder solution lasts for 7 days; in the whole experiment process, the modeling mouse and the common mouse are raised in a clean laboratory and are separately fed, and the litchi powder aqueous solution, the drinking water, the feed, the padding and the experimental apparatus are sterilized by high pressure before the experiment. After one week of gastric lavage, collecting fecal samples of a building module, namely a litchi powder-induced endotoxin infection model mouse and a control group, namely an HFA model mouse, placing the fecal samples in a prepared sterile centrifuge tube, and freezing and storing the fecal samples in an ultra-low temperature refrigerator at minus 80 ℃; and obtaining mouse serum from the mouse by eyeball hemospasia (blood at 3500 r.min)-1Centrifuging at 4 deg.C for 10min), and storing in refrigerator at 4 deg.C; after-sacrifice, dissect, and take 5cm above the cecum of the mouse during dissection, and soak the cecum in formalin solution.
2.3 group experiments
Selecting 20 litchi model mice, randomly dividing into 4 groups, and using 5 mice in each group as litchi model group (denoted as LM), mussel extract low dose group (denoted as ME.L), mussel extract medium dose group (denoted as ME.M) and mussel extract high dose group (denoted as ME.H), wherein 200mg/kg d is given to 3 groups of mussel extract low, medium and high dose groups respectively-1、400mg/kg·d-1And 800 mg/kg. d-1Mussel extract solution (each for 7 days). 5 HFA mice served as a control group and were gavaged with sterile water for 7 days.
Both the model mice and the normal mice were housed in a clean laboratory throughout the experiment and were fed individually. Mussel extract water solution, drinking water, feed, padding and testerAll were autoclaved before mechanical experiments. After one week of gastric lavage, collecting fecal samples of each group of mice, placing in a prepared sterile centrifuge tube, and freezing and storing in a-80 ℃ ultra-low temperature refrigerator; and obtaining mouse serum from each group of mice by eyeball hemospasia (blood at 3500 r.min)-1Centrifugation at 4 ℃ for 10min), storage in a refrigerator at 4 ℃.
3. Index measurement and results
3.1 analysis of the intestinal flora Structure of mice
Extracting DNA of excrement: extracting DNA from feces sample in-80 deg.C refrigerator by SDS lysate freeze thawing method, extracting genome DNA with PowerMax extraction kit (MoBio Laboratories, Carlsbad, CA, USA), and storing at-20 deg.C; the quantity and quality of DNA were determined using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA), and if the sample concentration was low, the sample was deemed invalid and no further electrophoretic detection was possible.
Illumina high-throughput 16s rDNA sequencing: performing amplification sequencing on a V4 region by adopting an Illumina Hiseq sequencing platform and using primers 515F-806R, sequencing to obtain initial data in a fastq format, and matching and splicing into a single sequence; determining a sample corresponding to the sequence by barcode, performing quality control filtration by using a QIIME sequence, and removing chimera to obtain an effective sequence.
3.1.1 OTU clustering and statistics
And writing a program by using R software, and counting the length distribution of the sequences contained in all the samples. According to the clustering result of the OTU, a Weinn graph is drawn by taking the OTU as a unit under the condition of 97% similarity as default, the number of the common and specific OTUs among different samples (groups) is compared, and the result is shown in figure 1.
As can be seen, compared with the humanized mouse control group, the litchi model group has 998 common OTU units, 298 increased OTU units and 490 decreased OTU units. The common OTU unit quantity of the low, medium and high dose mussel stem pre-group and the humanized mouse control group is 741, 973 and 1095 respectively, and is not significantly different from the litchi model group; the number of the three newly added OTU units is 486, 490 and 419 respectively, the difference in the group is not obvious, but is obviously higher than that of the litchi model group; the number of the OTU units reduced in the three groups is 747, 515 and 393, wherein the low dose group is obviously higher than that of the litchi model group, the medium dose is not obvious, and the reduction proportion of the high dose group to the litchi model group is smaller. It is demonstrated that medium and high doses of mussel extract are effective in regulating the decrease in the number of OTU units of the intestinal flora and the deviation of species organization caused by litchi.
3.1.2 analysis of the composition of the respective Classification level
And (4) obtaining the microbial community composition number of each sample at different classification levels (consisting of phyla, class, order, family, genus and species) through the statistics of the clustering and annotation results of the OTU. According to the species annotation result, a relative abundance histogram is drawn by selecting the species with the top abundance ranking 10 at each classification level (phylum, class, order, family and genus) of each sample or group, and the species composition proportion condition between different samples or groups is analyzed. And clustering according to the similarity of the classification units of different samples, and knowing the similarity between samples and the community composition similarity on the genus level.
3.1.2.1 comparison of differences in intestinal flora at the phylum level in mice following mussel extract intervention
As can be seen in FIG. 2, the proportional abundance of Mytilus edulis high dose group Proteobacteria (Proteobacteria) is significantly increased (p <0.05), and the proportion occupied by Bacteroides, Fusobacteria, Verrucomicrobia and some Other phyla (Unassigned; Other) is significantly decreased (p < 0.05).
3.1.2.2 comparison of differences in intestinal flora at genus level in mice following mussel extract intervention
As can be seen from fig. 3, the following genera were significantly reduced before and after intervention with different dosages of mussel extract: the genus under Enterobacteriaceae (Enterobacteriaceae) was significantly reduced by 34.64% in the low dose group and by 18.89% and 51.36% in the medium and high dose groups, respectively; the low, medium and high dose components of Lactobacillus (Lactobacillus) are respectively increased by 212.17%, 23.05% and 287.22%, and the difference is obvious. The low, medium and high dose fractions of the genus Cochlearbacium (Phascolarcotobacterium) were reduced by 59.67%, 16.23% and 51.88%, respectively. The key drivers of litchi inflammation-causing bacteria, namely the cholephilus (Bilophila), is remarkably reduced under litchi intervention, and the bacteria are respectively increased by 64.81 percent and 53.16 percent under the intervention of low and high doses of mussels; another inflammatory key driver, Megamonas (Megamonas), rose markedly with litchi intervention and declined markedly with mussel high dose intervention (p < 0.05).
3.1.3 mouse intestinal flora alpha diversity
The population diversity (Alpha diversity) index of the sample is calculated from the OTU abundance matrix, the abundance of the population (i.e. the number of microbial members such as OTUs in the population) is indicated using the Chao1 index and the ACE index, and the Shannon index and Simpson index reflect the uniformity of the population (i.e. the magnitude of the abundance difference between the members).
Chao1 abundance estimation index the number of species actually present in a community was estimated by counting the number of OTUs detected in the community only 1 and 2 times. The Shannon index comprehensively considers the abundance and uniformity of the community. The higher the Shannon index value, the higher the diversity of the community. The Simpson diversity index is also one of the commonly used indices for evaluating community diversity, with higher Simpson index values indicating higher community diversity. See table 1 for results.
TABLE 1 Change in alpha diversity index of intestinal flora in mice from different mussel dose groups
| Grouping | shannon | simpson | chao1 | ace | goods_coverage |
| LM | 5.50±0.62b | 0.88±0.09b | 1236±103.32b | 1217±96.24c | 0.99±0.01 |
| ME.L | 4.27±0.52a | 0.82±0.08a | 783±84.28a | 764±84.71b | 0.99±0.01 |
| ME.M | 4.35±0.68a | 0.84±0.13a | 732±97.42a | 716±88.34a | 0.99±0.01 |
| ME.H | 4.39±0.31a | 0.83±0.07a | 738±85.66a | 734±83.97b | 0.99±0.01 |
| HFA | 4.53±0.44a | 0.83±0.07a | 764±69.13a | 746±71.49b | 0.99±0.01 |
Note: the data in the same column are marked with different lower case letters to indicate significant difference (P <0.05), and the same or no letters to indicate insignificant difference (P > 0.05).
As can be seen from Table 1, the human mouse intestinal flora alpha diversity index of Chao1, Shannon and ace of litchi after modeling is remarkably increased (p is less than 0.05), while the model mouse has a remarkably reduced alpha diversity index (p is less than 0.05) after the mussel trunk, and is close to the level of a control group. The mussel intervention is shown to have the effect of reducing and recovering the diversity increase of intestinal flora caused by litchi.
3.1.4 mouse intestinal flora beta diversity
Classifying and combining a plurality of intestinal flora components according to the OTU abundance matrix, carrying out PCoA analysis based on the weighted Spearman distance, selecting a factor most representing the flora as a main coordinate axis for drawing, and showing the similarity and difference of the structures of the intestinal flora of the measured sample through a PCoA diagram; if the samples are closer together (i.e., the species are more similar in abundance and composition), they are closer together in the PCoA plot, and the results are shown in FIG. 4.
It can be seen from the figure that the litchi model group is greatly different from the control group when observed from the angle of PC1, and the low-dosage and high-dosage groups of the mussel extract are both similar to the control group to a certain extent, wherein the high-dosage group is the closest group. From the perspective of PC2, the litchi model groups were centrally distributed at the lower part, and the mussel high-dose group covered the area where the control group was located, indicating that there was a certain degree of similarity between the intestinal flora of the high-dose group and the intestinal flora of the control group mice. According to the three graphs, the high-dose mussel intervention can restore the species abundance and the composition deviation of the intestinal flora induced by litchi
3.2 measurement of LPS in mouse serum
The amount of LPS in the obtained mouse serum samples was determined strictly according to the kit procedures and the results are shown in FIG. 5.
As can be seen, the concentration level of LPS in the serum of the low-dose group of the mussels is obviously reduced by 22% (p is less than 0.5) compared with that of the group of the inflammation-causing model; the LPS concentration level in the serum of the medium-dose and high-dose groups of the mussel is extremely reduced, the reduction range is 36.12 percent and 34.03 percent (p is less than 0.05), and the LPS concentration level is not obviously different from that of the control group. The mussel extract with medium and high dose can better prevent LPS induced by litchi from entering blood.
3.3 determination of inflammatory factors in mouse serum
The contents of IL-10 and TNF-alpha in the obtained mouse serum sample are determined strictly according to the kit operation steps, and the results are shown in FIGS. 6-7.
As can be seen, compared with the humanized blank group, the low, medium and high dose groups of the mussel extract have significantly lower down-regulation effect on proinflammatory factor TNF-alpha in serum than that of the proinflammatory factor TNF-alpha in serum, and no significant difference exists among the three dose groups; the IL-10 in the serum of a mouse with a high dose of mussel extract is remarkably reduced, and the inflammation inhibiting effect is obvious; the result shows that the mussel extract with a certain dosage has obvious effect of relieving the low-grade inflammation of the body system induced by endotoxin.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Claims (10)
1. An application of mussel extract in preparing medicine for treating flora disorder is disclosed.
2. The use according to claim 1, wherein the medicament is capable of reducing the expression of pro-inflammatory factors in the body.
3. The use according to claim 2, wherein the proinflammatory factor is TNF- α.
4. The use of claim 1, wherein the medicament is capable of increasing the expression of an anti-inflammatory factor in the body.
5. The use of claim 4, wherein the anti-inflammatory agent is IL-10.
6. The use of claim 1, wherein the medicament is capable of reducing the endotoxin concentration of a body inflammatory factor.
7. The use of claim 1, wherein the medicament is capable of restoring normal abundance of key inflammatory flora in the gut flora.
8. The use of claim 7, wherein the restoration of normal abundance of key inflammatory flora in gut flora is the down-regulation of dietary-induced increase in gut flora diversity and restoration of abundance ratio of inflammatory driving flora megamonas and cholecystophila.
9. The use of claim 1, wherein the mussel extract is prepared by:
drying and crushing mussels, adding water with the mass volume ratio of 1 (3-10) g/ml, extracting at 40-60 ℃ for 3-6 h, filtering, adding soluble starch, and spray drying to obtain the mussel extract with the mass of 10% of the mussel raw material.
10. The use according to claim 9, wherein the temperature of the extraction is 50-60 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011038359.XA CN112089734A (en) | 2020-09-28 | 2020-09-28 | Application of mussel extract in preparation of medicament for treating flora disorder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011038359.XA CN112089734A (en) | 2020-09-28 | 2020-09-28 | Application of mussel extract in preparation of medicament for treating flora disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112089734A true CN112089734A (en) | 2020-12-18 |
Family
ID=73783808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011038359.XA Pending CN112089734A (en) | 2020-09-28 | 2020-09-28 | Application of mussel extract in preparation of medicament for treating flora disorder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112089734A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107427547A (en) * | 2015-03-24 | 2017-12-01 | 新西兰植物与食品研究所 | Water-soluble mussel extract |
| CN109090620A (en) * | 2018-08-09 | 2018-12-28 | 山东省药学科学院 | A kind of application of mussel polysaccharide and its catabolite |
-
2020
- 2020-09-28 CN CN202011038359.XA patent/CN112089734A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107427547A (en) * | 2015-03-24 | 2017-12-01 | 新西兰植物与食品研究所 | Water-soluble mussel extract |
| CN109090620A (en) * | 2018-08-09 | 2018-12-28 | 山东省药学科学院 | A kind of application of mussel polysaccharide and its catabolite |
Non-Patent Citations (3)
| Title |
|---|
| 孙东方: "基于肠道菌群探究贻贝提取物对食物有道的系统低度验证的干预作用", 《中国优秀博硕士学位论文全文数据库（硕士） 工程科技I辑》 * |
| 孙东方: "基于肠道菌群探究贻贝提取物对食物有道的系统低度验证的干预作用", 《中国优秀博硕士学位论文全文数据库（硕士） 工程科技I辑》, 15 February 2021 (2021-02-15) * |
| 李玉环等: "贻贝蛋白-多糖热水同提工艺及抽提物的研究", 《钦州学院学报》, vol. 32, no. 7, pages 227 - 228 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Akgül et al. | The role of probiotics in women with recurrent urinary tract infections | |
| Han et al. | Dietary grape seed proanthocyanidins (GSPs) improve weaned intestinal microbiota and mucosal barrier using a piglet model | |
| US9603876B2 (en) | Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment | |
| Justino et al. | Regulatory role of Lactobacillus acidophilus on inflammation and gastric dysmotility in intestinal mucositis induced by 5-fluorouracil in mice | |
| Cox et al. | Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences | |
| AU2017299137B2 (en) | Use of probiotics in the treatment and/or prevention of atopic dermatitis | |
| EP3222282A1 (en) | Use of probiotics in the treatment and/or prevention of psoriasis | |
| Hatanaka et al. | Effect of Bacillus subtilis C-3102 on loose stools in healthy volunteers | |
| Peng et al. | Enterococcus faecium NCIMB 10415 administration improves the intestinal health and immunity in neonatal piglets infected by enterotoxigenic Escherichia coli K88 | |
| WO2020063553A1 (en) | Bifidobacterium lactis bl-99 and application thereof | |
| CN114650833A (en) | Compositions and methods for treating autism spectrum group disorders | |
| US20210121511A1 (en) | Virus-like particle compositions and methods of using same | |
| Xie et al. | Bacterial diversity in intestinal mucosa of antibiotic-associated diarrhea mice | |
| Gaspardo et al. | Influence of Lactobacillus kefiri on intestinal microbiota and fecal IgA content of healthy dogs | |
| KR20200138333A (en) | Compositions and methods for treating inflammatory bowel disease | |
| US20240050494A1 (en) | Probiotics compositions and method of using the same to enhance growth and social function in children | |
| CN111246870B (en) | Grape skin for treating dysbiosis | |
| WO2021097288A1 (en) | Compositions and methods for treating neurodegenerative diseases | |
| CN115279382A (en) | Compositions and methods for delivering bacterial metabolites to a subject | |
| CN107847483A (en) | Antibiotic with particular treatment activity and the Bacillus acidi lactici with identical treatment idicatio with not transferable antibiotic resistance and/or Bifidobacterium at the same associated with apply | |
| CN112089734A (en) | Application of mussel extract in preparation of medicament for treating flora disorder | |
| Merenstein et al. | Short-term, daily intake of yogurt containing Bifidobacterium animalis ssp. lactis Bf-6 (LMG 24384) does not affect colonic transit time in women | |
| Da Silva et al. | Long-term diosmectite use does not alter the gut microbiota in adults with chronic diarrhea | |
| CN112076220A (en) | Application of shrimp head zymolyte in preparing medicine for regulating intestinal flora or relieving constipation | |
| CN117106622B (en) | Lactobacillus plantarum and application of composition thereof in preparation of medicines for treating internal hemorrhoids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |